---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Natural history, survival, and mortality"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Natural history, survival, and mortality. Topics: Lesion growth: pooled rate across natural history studies, Lesion growth: constant radial enlargement in untreated eyes, Lesion growth: AREDS2 cohort, Lesion growth: AREDS cohort, and 15 further topics. 19 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Lesion growth: pooled rate across natural history studies

> “The pooled mean GA growth rate was 1.66 mm2/year (SD = 1.27 mm2/year, I2 = 97.0%, p < 0.001) from 23 studies (3,078 patients) reported with growth rate in mm2/year and 0.33 mm/year (SD = 0.17 mm/year, I2 = 83.0%, p < 0.001) from 12 studies (1,808 patients) reported with growth rate in mm/year. Larger mean baseline GA area in mm2 was associated with larger mean growth rate in both mm2/year and mm/year (p < 0.001).”

Source: [Wang and Ying (2021)](https://pubmed.ncbi.nlm.nih.gov/32721951/)

<a id="topic-2.2.1.3-2"></a>

### Lesion growth: constant radial enlargement in untreated eyes

> “We included 25 studies with data from 2942 eyes. The RLM yielded the best goodness of fit and predictive performance of GA progression.”
> “The GA radius enlarged at a constant rate of 0.163 mm/year (95% confidence interval, 0.158-0.167 mm/year), which was independent of time (r = -0.108). The RLM predicted the mean age of onset of GA as 67.4±5.2 years.”

Source: [Shen et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/31047226/)

<a id="topic-2.2.1.3-3"></a>

### Lesion growth: AREDS2 cohort

> “In the prevalence cohort, the change over time in square root of GA area was 0.29 mm/year (95% CI 0.27–0.30), i.e. 0.17 disc diameters/year, or (without square root transformation) 1.42 mm2/year (1.33–1.52), i.e. 0.61 disc areas/year.”
> “GA enlargement was significantly faster for non-central than for central GA at 0.31 mm/year (0.30–0.33) and 0.22 mm/year (0.20–0.24), respectively.”

Source: [Keenan et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6246813/)

<a id="topic-2.2.1.3-4"></a>

### Lesion growth: AREDS cohort

> “Median initial lesion size was 4.3 mm2. Average change in digital area of GA from baseline was 2.03 mm2 (standard error of the mean, 0.24 mm2) at 1 year, 3.78 mm2 (0.24 mm2) at 2 years, 5.93 mm2 (0.34 mm2) at 3 years, and 1.78 mm2 (0.086 mm2) per year overall.”

Source: [Lindblad et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6500457/)

<a id="topic-2.2.1.3-5"></a>

### Lesion growth: prospective single-center natural history study

> “The median overall enlargement rate was 2.1 mm2/year (mean, 2.6 mm2/year). Eyes with larger areas of atrophy at baseline tended to have larger enlargement rates, but knowledge of prior rates of enlargement was the most significant factor in predicting subsequent enlargement rates.”

Source: [Sunness et al. (2007)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2562326/)

<a id="topic-2.2.1.3-6"></a>

### Lesion growth and visual acuity loss over 24 months in the Proxima A and B studies

> “At 24 months, adjusted mean (standard error) change in GA lesion area from baseline was 3.87 (0.15) mm2 in participants with bilateral GA (Proxima A), 3.55 (0.16) mm2 in the fellow eye CNV cohort (Proxima B), and 2.96 (0.25) mm2 in the fellow eye intermediate AMD cohort (Proxima B).”
> “Adjusted mean (standard error) changes in BCVA and LLVA (ETDRS letters) in the study eye from baseline to 24 months were -13.88 (1.40) and -7.64 (1.20) in Proxima A, -9.49 (1.29) and -7.57 (1.26) in Proxima B fellow eye CNV cohort, and -11.48 (3.39) and -8.37 (3.02) in Proxima B fellow eye intermediate AMD cohort, respectively.”

Source: [Holekamp et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32081489/)

<a id="topic-2.2.1.3-7"></a>

### Foveal progression: time from noncentral to central geographic atrophy in AREDS

> “Median time to developing central GA after any GA diagnosis was 2.5 years (95% confidence interval, 2.0-3.0). Average visual acuity decreased by 3.7 letters at first documentation of central GA, and by 22 letters at year 5.”

Source: [Lindblad et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6500457/)

<a id="topic-2.2.1.3-8"></a>

### Foveal progression: 2-year and 4-year rates in AREDS2

> “For the 628 participants (and 734 eyes) whose incident GA was non-central GA at its first appearance, mean follow-up time was 4.7 years (SD 0.8; IQR 0.7). The Kaplan-Meier plot for the progression from non-central to central GA in these eyes is shown in Figure 5, with a 32% 2-year rate and a 57% 4-year rate of progression to central GA.”

Source: [Keenan et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6246813/)

<a id="topic-2.2.1.3-9"></a>

### Foveal progression: 5-year change in a U.S. population-based cohort

> “Of 53 eyes with multiple visits, the overall increase in atrophy was 6.4 mm2 over a 5-year period. The atrophy progressed to involve the foveal center in 47% of eyes and there was a mean decrease of 17 letters read correctly.”

Source: [Klein et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2612630/)

<a id="topic-2.2.1.3-10"></a>

### Foveal progression and visual acuity change over 24 months in the IRIS Registry

> “In total, 69 441 patients were included: 44 120 (64%) GA:GA and 25 321 (36%) GA:nAMD.”
> “In both GA:GA and GA:nAMD cohorts, nonsubfoveal study eyes had better mean (standard deviation) VA at index (67 [19.3] and 66 [20.3] letters) than subfoveal eyes (59 [23.9] and 47 [26.9] letters), and 24-month mean VA changes were similar for nonsubfoveal (−7.6 and −6.2) and subfoveal (−7.9 and −6.5) subgroups. Progression to subfoveal GA occurred in 16.7% of nonsubfoveal study eyes in the GA:GA cohort and 12.5% in the GA:nAMD cohort. More new-onset study-eye nAMD was observed in the GA:nAMD (21.6%) versus GA:GA (8.2%) cohorts.”

Source: [Rahimy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10232896/)

<a id="topic-2.2.1.3-11"></a>

### Foveal progression in U.S. Medicare Advantage claims

> “At index, 4,781 (50.3%) individuals had GA without SFI and 4,697 (49.4%) had GA with SFI. Among individuals with GA without SFI at index, 479 (10.2%) progressed to GA with SFI during the 12-month follow-up.”
> “Significant predictors of progression to GA with SFI were wet AMD at baseline (HR [CI] = 5.70 [4.63-6.99], P < 0.001)”

Source: [Saundankar et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695847/)

<a id="topic-2.2.1.3-12"></a>

### Visual acuity loss: annual rate in AREDS2

> “The overall change in BCVA over time was significantly less than 0 at −2.3 letters/year (−2.6 to −2.0; p<0.0001).”

Source: [Keenan et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6246813/)

<a id="topic-2.2.1.3-13"></a>

### Visual acuity loss over 4 years by baseline acuity and lesion proximity to the fovea

> “We included 1351 eyes from 994 participants, including 594 eyes from 464 participants with 4-year BCVA follow-up.”
> “In contrast, 483 eyes that met both criteria of baseline BCVA ≥ 40 letters and GA lesions involving or within 1 mm of the foveal center showed significant BCVA loss over 4 years (mean change = −11.33 letters [95% confidence interval = −12.80 to −9.84]), with faster GA progression associated with larger BCVA loss (P < 0.001).”

Source: [Shen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13474407/)

<a id="topic-2.2.1.3-14"></a>

### Visual acuity loss over 2 years in the lampalizumab trials

> “Approximately 75%, 50%, and 25% of study eyes experienced a ≥5-, ≥10-, and ≥15-letter loss by 2 years, respectively.”

Source: [Anegondi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39581330/)

<a id="topic-2.2.1.3-15"></a>

### Visual acuity loss and progression to neovascular AMD in bilateral geographic atrophy in U.K. practice

> “In the worse-seeing eye, 40.1% lost ≥10 letters in 2.4 years. Among patients with baseline and 24-month VA measurements, mean VA decline was 6.1 letters in the worse-seeing eye (n = 413) and 12.4 letters in the better-seeing eye (n = 414). The rate of progression to CNV in either eye was 7.4% per patient-year.”

Source: [Chakravarthy et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29366564/)

<a id="topic-2.2.1.3-16"></a>

### Progression to neovascular AMD after incident geographic atrophy in AREDS2

> “In eyes with incident GA, 4-year risk of subsequent neovascular AMD was 29%.”

Source: [Keenan et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6246813/)

<a id="topic-2.2.1.3-17"></a>

### Progression from unilateral to bilateral geographic atrophy

> “Interestingly, we found that the median time to development of bilateral GA was 7 years.”

Source: [Lindblad et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6500457/)

<a id="topic-2.2.1.3-18"></a>

### Mortality: total area of geographic atrophy and all-cause mortality

> “During a median follow-up of 6.8 years, 48 (23.0%) participants with GA died. In adjusted models, accounting for age, sex, and health status, participants with total GA area in the highest quartile had a significantly increased risk of all-cause mortality compared to those with total GA area in the lowest quartile (hazard ratio [HR], 3.42; 95% confidence interval [CI], 1.32-8.86; P = 0.011). GA effective radius growth rate, bilateral disease, and the presence of foveal center involvement were not significantly associated with mortality.”

Source: [Ahluwalia et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33742280/)

<a id="topic-2.2.1.3-19"></a>

### Mortality: late AMD and all-cause and cardiovascular mortality (geographic atrophy and neovascular AMD combined)

> “Late AMD was associated with elevated rates of all-cause (nine studies, hazard ratio (HR) 1.20, 95% confidence interval, CI, 1.02-1.41) and cardiovascular mortality (six studies, HR 1.46, 95% CI 1.13-1.98), but early AMD was not (all-cause mortality, 10 studies, HR 1.06, 95% CI 0.98-1.14; cardiovascular mortality, five studies, HR 1.12, 95% CI 0.96-1.31).”

Source: [McGuinness et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28139151/)

> “The risk of all-cause mortality and cardiovascular mortality associated with early AMD were 1.08 (1.00-1.18) and 1.05 (0.89-1.24), and the associations with late AMD were 1.23 (1.11-1.36) and 1.28 (1.04-1.57), respectively.”

Source: [Xin et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28665868/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
